{"groups":[{"description":"Participants received obinutuzumab, 1000 milligrams (mg) as an intravenous (IV) infusion on Day 1 and Weeks 2, 24, 26, and either Weeks 50 and 52 or Week 52 only, along with mycophenolate mofetil (MMF) and SOC therapy. Placebo was administered at Week 50 for participants not treated with obinutuzumab. Participants with adequate response at Week 76 continued to receive obinutuzumab at Week 80 and every 6 months (Q6M) thereafter. The dose of MMF can be adjusted at the investigator's discretion beginning at Week 80.","id":"FG000","title":"Obinutuzumab"},{"description":"Participants received Obinutuzumab matching placebo as an IV infusion on Day 1 and Weeks 2, 24, 26, 50, and 52. Participants also received SOC therapy and MMF. Participants with adequate response at Week 76 continued to receive placebo at Week 80 and Q6M thereafter. The dose of MMF can be adjusted at the investigator's discretion beginning at Week 80.","id":"FG001","title":"Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"4"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Non-compliance with Study Drug"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"5"}],"type":"Reason not Specified"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"6"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"14"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"116"},{"groupId":"FG001","numSubjects":"102"}],"type":"Ongoing in the Study"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"135"},{"groupId":"FG001","numSubjects":"136"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"136"},{"groupId":"FG001","numSubjects":"132"}],"comment":"Safety evaluable population included all participants who received any part of blinded infusion of Obinutuzumab/placebo \\& are grouped according to treatment they received. 3 participants from placebo arm were excluded from the safety analysis as they received no treatment post-randomization. 1 participant randomized to the placebo arm received obinutuzumab \\& was included in the obinutuzumab arm for safety analysis.","type":"Safety Population"},{"achievements":[{"groupId":"FG000","numSubjects":"122"},{"groupId":"FG001","numSubjects":"120"}],"type":"Completed Week 76 Assessment"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"135"},{"groupId":"FG001","numSubjects":"136"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants were randomized in a 1:1 ratio to Obinutuzumab/placebo. As pre-specified in the statistical analysis plan (SAP), participant flow data for all participants randomized to 1 of the 2 dosing schedules of obinutuzumab (Groups 1 \\& 2) were reported in the combined obinutuzumab treatment group. This study is ongoing.","recruitmentDetails":"A total of 271 participants with International Society of Nephrology/ Renal Pathology Society (ISN/RPS) 2003 Class III or IV lupus nephritis (LN) treated with standard-of-care (SOC) therapy took part in the study across 72 sites in 15 countries.\n\nThis study consists of blinded treatment with obinutuzumab or placebo, followed by open-label treatment (OLT) with obinutuzumab."}